

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 1 120 107 A1

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:

01.08.2001 Bulletin 2001/31

(21) Application number: 01400198.6

(22) Date of filing: 25.01.2001

(51) Int Cl.7: **A61K 7/48, A61K 35/78, A61K 31/23, A61K 31/07, A61K 31/455, A61K 31/355, A61K 31/375, A61K 33/04, A61P 17/00, A23L 1/30**

(84) Designated Contracting States:

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

Designated Extension States:

AL LT LV MK RO SI

(30) Priority: 26.01.2000 FR 0000975

(71) Applicant: **Johnson & Johnson Consumer France**
92130 Issy les Moulineaux (FR)

(72) Inventors:

- **Castelli, Dominique**
75017 Paris (FR)
- **Issachar, Nathalie**
75016 Paris (FR)

(74) Representative: **Martin, Jean-Jacques et al**
Cabinet Régimbeau
20, rue de Chazelles
75847 Paris cedex 17 (FR)

(54) **Nutritional supplement based on blackcurrant seed oil**

(57) The present invention relates to the use of a composition comprising an oil with a high content of essential fatty acids of $\omega 3$ and $\omega 6$ type, preferably blackcurrant seed oil, and at least one compound selected from β -carotene, lycopene, tocopherol and its deriva-

tives, tocotrienols and their derivatives, ascorbic acid and nicotinamide, as a nutritional supplement intended for preventing and/or combating the harmful effects of xenobiotics on the skin, in particular on the skin's immune system.

EP 1 120 107 A1

Description

[0001] The present invention relates to the use of a composition comprising an oil with a high content of essential fatty acids of $\omega 3$ and $\omega 6$ type, preferably blackcurrant seed oil, and at least one compound selected from β -carotene, lycopene, tocopherol and its derivatives, tocotrienols and their derivatives, ascorbic acid and nicotinamide as a nutritional supplement intended for preventing and/or combating the harmful effects of xenobiotics on the skin, in particular on the skin's immune system.

[0002] The skin is continually in contact with xenobiotics, which are substances that are referred to as being foreign to the cell's natural metabolic pathways, such as medicinal products, pesticides, pollutants, tobacco or UV. The skin suffers daily attack when it is exposed to these agents, in particular to UV rays which cause immediate damage to the skin, such as sunburn, photosensitivity or immunosuppression reactions, but also long-term effects such as photo-ageing or skin tumours.

[0003] Most of these adverse effects are associated with the production of oxygenated free radicals. They have the property of depolymerizing certain skin constituents such as collagen or elastin, or else of degrading membrane lipids or DNA, which results in the production of endobiotics that are harmful to the skin, such as toxic metabolites or inflammation mediators which finally lead to a loss of integrity of the cell membranes. The action of xenobiotics and endobiotics is particularly important as regards the skin's immune defences. Specifically, a depletion of the Langerhans cells can result in a penetration of pathogens into the body without the general immune system being alerted.

[0004] This results, for example, in a higher propensity for the appearance of infections via pathogens.

[0005] The use of compounds capable of inhibiting or neutralizing the action of xenobiotics and endobiotics, in particular oxygenated free radicals, might make it possible to reduce the skin damage induced.

[0006] Among these compounds, vitamins and essential fatty acids have, in a certain number of *in vitro* and *in vivo* studies, shown protective activity with respect to harmful xenobiotics and endobiotics. α -Tocopherol has shown that it can prevent the oxidation of polyunsaturated fatty acids, which are essential components of cell membranes and are particularly sensitive to damage induced by free radicals (1). This compound also has anti-inflammatory activity by means of direct action on the enzymatic systems of the arachidonic cascade (2). Other components belonging to the tocotrienol family (α -, γ -tocotrienols and their derivatives) have shown noteworthy action in preventing cell damage associated with an exposure of the skin and the superficial body growths to free radicals and UV rays (3) and to ozone (4). In addition, it has been demonstrated that the role of tocopherols and tocotrienols is important as regards the activation of the immune system (5).

[0007] Ascorbic acid can also trap the oxygenated free radicals (more particularly singlet oxygen) involved in many oxidative processes which damage cells (6). In addition, α -tocopherol combined with ascorbic acid shows effects on increasing the Minimum Erythral Dose (7).

[0008] β -Carotene is a vitamin A precursor which acts as a chemical screening agent (with an absorption maximum in the UVA and visible range) and protects against lipid peroxidation (8, 9). It is often used to prevent photodermatoses (10). In general, carotenoids (β -carotene, lycopene, lutein, zeaxanthin and astaxanthin) are also involved in modulating the immune system (WO 98/44808). Lycopene is also a free-radical trap (11) and nicotinamide is often used in the same way as a β -carotene against photodermatoses (12).

[0009] Blackcurrant seed oil, which contains essential fatty acids of $\omega 3$ and $\omega 6$ type, has shown a certain level of efficacy in reducing certain inflammatory processes (13).

[0010] In the context of the present invention, it has been found, surprisingly, that a combination between blackcurrant seed oil and the abovementioned compounds has, in a nutritional composition, an advantageous effect for reducing the harmful action of both xenobiotics and endobiotics of the free-radical type or of the type generating free radicals, in particular by reinforcing the skin's immune defences. After repeated daily administration, such a composition affords protection to the Langerhans cells.

Description

[0011] Thus, the present invention relates to the use of a composition comprising an oil with a high content of essential fatty acids of the type $\omega 3$ and $\omega 6$ and at least one compound selected from β -carotene, lycopene, tocopherol and its derivatives, tocotrienols and their derivatives, ascorbic acid and its derivatives, nicotinamide and a trace element, as a nutritional supplement intended for reinforcing the immune defences of the skin and the superficial body growths.

[0012] More specifically, this nutritional supplement may be intended for preventing and/or combating the harmful effects of xenobiotics on the skin, in particular on the skin's immune system, in particular for reducing the cytotoxic effects of xenobiotics on the Langerhans cells. In this sense, the composition according to the invention is useful for combating or preventing photodermatoses, for improving the skin's tolerance to sunlight and for preventing ageing of the skin and the superficial body growths and their disequilibrium due to free radicals.

[0013] In one advantageous embodiment, the composition comprises blackcurrant seed oil, since this oil is rich in

essential fatty acids of $\omega 3$ and $\omega 6$ type, in particular α -linoleic acid, α -linolenic acid and γ -linolenic acid.

[0014] This oil comprises:

- Palmitic acid	C16:0	6-8%
- Stearic acid	C18:0	1-2%
- Oleic acid $\omega 9$	C18:1, $\Delta 9$	9-13%
- Linoleic acid $\omega 6$	C18:2, $\Delta 9,12$	44-51%
- γ -Linolenic acid $\omega 6$	C18:3, $\Delta 8,9,12$	15-20%
- α -Linolenic acid $\omega 3$	C18:3, $\Delta 9,12,15$	12-14%
- Stearidonic acid $\omega 3$	C18:4, $\Delta 6,9,12,15$	2-4%

[0015] Essentially, the $\omega 3$ fatty acids have a beneficial effect on erythema induced by UVB and are useful in the prevention of photocarcinogenesis. The $\omega 6$ fatty acids are particularly important in the context of the invention since they participate in keratinization.

[0016] Needless to say, an oil equivalent to blackcurrant seed oil in terms of the abovementioned essential fatty acid composition can be used in the dietary supplement described according to the invention.

[0017] In one preferred aspect of the invention, the composition comprises blackcurrant seed oil, β -carotene, lycopene, tocopherol or its derivatives, tocotrienols or their derivatives, ascorbic acid or its derivatives, and nicotinamide.

[0018] The composition can also comprise a trace element, preferably selenium in any form, in particular in the form of selenium-containing yeasts.

[0019] Selenium is a co-factor which increases the activity of glutathione peroxidase (GPX), protects cells against the harmful effects of organic and inorganic peroxides, and stabilizes membranes by becoming incorporated into the disulphide bridges, thus leading to a decrease in the amount of arachidonic acid released during the inflammatory response. Thus, this compound is also useful as a compound for protecting the skin against xenobiotics.

[0020] The composition advantageously comprises at least 25% by weight, preferably about 50%, of blackcurrant seed oil. It can also comprise

- at least 5% by weight, preferably 15 to 18%, of ascorbic acid;
- at least 4% by weight, preferably about 8%, of lycopene;
- at least 5% by weight, preferably about 10%, of selenium;
- at least 2% by weight, preferably about 4%, of β -carotene;
- at least 1% by weight, preferably about 3%, of nicotinamide;
- and/or at least 1% by weight, preferably about 2%, of tocopherol or its derivatives, in particular tocopheryl acetate.

[0021] A composition according to the invention may thus comprise approximately, by weight:

- 53% blackcurrant seed oil,
- 4% β -carotene,
- 8% lycopene,
- 2.2% tocopheryl acetate,
- 15 to 18% ascorbic acid, and
- 3% nicotinamide;
- and optionally about 10% by weight of selenium.

[0022] Among the excipients which are added, those preferably selected are yellow beeswax, soybean lecithin, glycerol, liquid paraffin and gelatin, preferably of marine nature.

[0023] Needless to say, it is possible to add to the composition any other active compound known in the prior art. Mention may be made, for example, of nucleic acids or nucleotides, amino acids, in particular lysine and arginine, peptides, sugars, in particular biologically active sugars, retinoids, plant extracts, in particular from green tea or from soybean, any extracts from plants rich in isoflavones, DHEA and melatonin.

[0024] The composition according to the invention can be in the form of gel capsules, soft capsules, sugar-coated or plain tablets, including delayed forms, suitable for oral administration. Thus, the invention relates to a composition as defined above.

Key to the figures

[0025] Figure 1: Efficacy of the oral supplement according to the invention on an erythema induced by UV. Meas-

urement of the variation in the 1-month and 3-month minimum erythema dose.

Figure 2: Efficacy of the oral supplement according to the invention on an erythema induced by UV. Measurement of the variation in the average intensity of erythema at 3 months (oral composition + factor 16 antisun cream and placebo + factor 16 antisun cream).

Figure 3: Efficacy of the oral supplement according to the invention on the depletion of Langerhans cells induced by UV. Measurement of the variation in the number of Langerhans cells ($p < 0.05$).

Figure 4: Efficacy of the oral supplement according to the invention on lipid peroxidation. Measurement of the variation in the amount of squalene peroxides.

Example 1: Preferred composition No. 1 of the invention

[0026]

	% by weight	Amount (mg/gel capsule)
Blackcurrant seed oil	53%	121.983
30% synthetic β -carotene	4%	9.2
6% lycopene	8%	19.167
α -Tocopheryl acetate	2.2%	5.25
Ascorbic acid	15 to 18%	34.5 to 42.0
Nicotinamide	3%	6.9
Excipients:		
Yellow beeswax, soybean lecithin, glycerol, liquid paraffin, fish gelatin, dyes		qs 230

Example 2: Preferred composition No. 2 of the invention

[0027] The composition is identical to the one described in Example 1, but in addition contains selenium $\approx 10\%$; i.e. 23.5 mg/gel capsule.

Example 3: Effects of the composition on protection against xenobiotics and on the reinforcement of the skin's immune defences, demonstrated in a double-blind clinical study versus placebo.

[0028] 2 groups of 20 healthy volunteers including individuals with sensitive skin (minimum 8) were included after having signed a free, explained and express consent.

1st group (20 volunteers): 2 capsules containing the active agents taken orally per day for 90 consecutive days (3 months).

2nd group (20 volunteers): 2 capsules of the placebo (without active ingredients) taken orally per day for 90 days (3 months).

Measurements

[0029] The Minimum Erythema Dose (MED), or weakest perceptible redness with clearly defined edges, was determined on the back of the volunteers participating in the study, according to the recommendations of Colipa, before, 1 month after and 3 months after the start of the oral supplementation.

[0030] The capacity imparted by this supplementation to reinforce the protection afforded by an antisun cream (sun protection factor 16) was furthermore evaluated before and after the 3 months of treatment and was compared with the efficacy of the antisun cream alone.

Biopsies

[0031] Superficial skin samples were taken from the lower back of 10 volunteers from each group, using a circular bistoury (punch) 4 mm in diameter, 24 hours after irradiation with 1 MED.

[0032] The biopsies were then fixed with Bouin's fluid, included in paraffin and then sliced in series in order to be

developed by immunohistochemistry to reveal the Langerhans cells (use of mouse clone 010 IgG1 monoclonal antibody, from the Immunotech laboratory, which recognises a specific membrane marker of the Langerhans cell, CD1a).

Results

[0033] All the results and the statistical comparisons are given in Figures 1-4 hereinbelow.

[0034] The oral supplementation studied significantly reinforces the skin's resistance to sunlight, compared with its placebo:

- increase in the minimum erythral dose (Figure 1),
- increase in the efficacy of a topical antisen screening agent (Figure 2),
- effect on the skin's immune system, by reducing the depletion of the Langerhans cells which is induced by UV (Figure 3),
- scavenging of the free radicals induced by UV (squalene hydroxyperoxides) (Figure 4).

[0035] This combination of vitamins (α -tocopherol, ascorbic acid, β -carotene, lycopene and nicotinamide) and of blackcurrant seed oil which contains essential fatty acids thus appears to be indicated in the prevention of adverse effects induced by xenobiotics, in particular for reinforcing the skin's immune defences.

REFERENCES

[0036]

- 1 - SUGIYAMA M., DATSUYUKI K., MATSUMOTO R. et al, Effect of vitamin E on cytotoxicity, DNA single strand breaks, chromosomal aberration and mutation in Chinese hamster V-79 cells exposed to ultraviolet-B light. Photochem. Photobiol. 1992, 56 (1): 31-34.
- 2 - LOPEZ-TORRES M., THIELE J.J., SHINDO Y. et al, Topical application of α -tocopherol modulates the antioxidant network and diminishes ultraviolet-induced oxidative damage in murine skin. Br. J. Dermatol. 1998, 138: 207-215.
- 3 - KITAZAWA M. et al, Photochemistry and Photobiology, 1997, Vol 65: 355-365.
- 4 - THIELE J. et al, FEBS LETTERS, Vol 401, Jan 20: 167-170.
- 5 - MEYDANI M. The Lancet, 21 Jan 1995, Vol 345, 170: 176
- 6 - DARR D., COMBS S., et al, Topical vitamin C protects porcine skin from ultraviolet radiation-induced damage. Br. J. Dermatol. 1992, 127: 247-253.
- 7 - EBERLEIN-KONIG, PLACZEC M., PRZYBILLA B. Protective effect against sunburn of combined systemic ascorbic acid (vitamin C) and d- α -tocopherol (vitamin E). J. Am. Acad. Dermatol. 1998, 38: 45-48.
- 8 - SOMEYA K. The effect of natural carotenoid (palm fruit carotene) intake on skin lipid peroxidation in hairless mice. J. Nutr. Sci. Vitaminol. 1994, 410: 303-314.
- 9 - ALEXANDER M., NEWMARK H.K., MILLER R.G. Oral β -carotene can increase the number of OKT4+ cells in human blood. Immunol. Lett. 1985, 9: 221-224.
- 10 - MATHEWS-ROTH M. Systemic photoprotection. Dermatologic Clinics. 1986, 4 (2): 335-339.
- 11 - DI MASCIO D. Lycopene as the most efficient biological carotenoid singlet oxygen quencher. Acta Biochem. Biophys. 1989, 274: 532-538.
- 12 - NEUMANN R., RAPPOLD E., POHL-MARKL H. Treatment of polymorphous light eruption with nicotinamide: A pilot study. Br. J. Dermatol. 1986, 115: 77-80.
- 13 - GUICHARDANT M., TRAITLER H., SPIELMAN D. et al. Stearidonic acid, an inhibitor of the 5-lipoxygenase

pathway. A comparison with timnodonic and dihomogammalinoleic acid. Lipids. 1993, 28 (4): 321-324.

Claims

1. Use of a composition comprising at least 25 % by weight of blackcurrant seed oil and at least one compound selected from β -carotene, lycopene, tocopherol and its derivatives, tocotrienols and their derivatives, ascorbic acid and its derivatives, nicotinamide and a trace element, as a nutritional supplement intended for reinforcing the immune defences of the skin and the superficial body growths.
2. Use of a composition comprising at least 25 % by weight of blackcurrant seed oil and at least one compound selected from β -carotene, lycopene, tocopherol and its derivatives, ascorbic acid and nicotinamide, as a nutritional supplement intended for preventing and/or combating the harmful effects of xenobiotics on the skin, in particular on the skin's immune system.
3. Use according to either of Claims 1 and 2, characterized in that the composition is intended for reducing the cytotoxic effects of xenobiotics on the Langerhans cells.
4. Use according to one of the preceding claims for combating and/or preventing photodermatoses.
5. Use according to one of the preceding claims, for improving the skin's tolerance to sunlight.
6. Use according to one of the preceding claims, for preventing ageing of the skin and the superficial body growths and their disequilibrium due to free radicals.
7. Use according to one of the preceding claims, characterized in that the composition comprises blackcurrant seed oil, β -carotene, lycopene, tocopherol or its derivatives, ascorbic acid and nicotinamide.
8. Use according to one of the preceding claims, characterized in that the composition also comprises a trace element, preferably selenium.
9. Use according to one of the preceding claims, characterized in that the composition comprises about 50% by weight of blackcurrant seed oil.
10. Use according to one of the preceding claims, characterized in that the composition comprises at least 5% by weight, preferably 15 to 18%, of ascorbic acid.
11. Use according to one of the preceding claims, characterized in that the composition comprises at least 4% by weight, preferably about 8%, of lycopene.
12. Use according to one of the preceding claims, characterized in that the composition comprises at least 5% by weight, preferably about 10%, of selenium.
13. Use according to one of the preceding claims, characterized in that the composition comprises at least 2% by weight, preferably about 4%, of β -carotene.
14. Use according to one of the preceding claims, characterized in that the composition comprises at least 1% by weight, preferably about 3%, of nicotinamide.
15. Use according to one of the preceding claims, characterized in that the composition comprises at least 1% by weight, preferably about 2%, of tocopherol or its derivatives, in particular tocopheryl acetate.
16. Use according to one of the preceding claims, characterized in that the composition comprises approximately, by weight:
 - 53% blackcurrant seed oil,
 - 4% β -carotene,
 - 8% lycopene,

EP 1 120 107 A1

- 2.2% tocopheryl acetate,
- 15 to 18% ascorbic acid,
- and 3% nicotinamide.

5 17. Use according to Claim 16, characterized in that the composition also comprises about 10% by weight of selenium.

18. Use according to one of the preceding claims, characterized in that the composition also comprises at least one excipient chosen from yellow beeswax, soybean lecithin, glycerol, liquid paraffin and gelatin.

10 19. Use according to one of the preceding claims, characterized in that the composition is in the form of gel capsules suitable for oral administration.

20. Composition as defined in any one of the preceding claims.

15

20

25

30

35

40

45

50

55




FIGURE 1




FIGURE 2




FIGURE 3




FIGURE 4



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 01 40 0198

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
X	WU D ET AL: "EFFECT OF DIETARY SUPPLEMENTATION WITH BLACK CURRAT SEED OIL ON THE IMMUNE RESPONSE OF HEALTHY ELDERLY SUBJECTS" AMERICAN JOURNAL OF CLINICAL NUTRITION, BETHESDA, MD, US, vol. 70, no. 4, July 1999 (1999-07), pages 536-543, XP000953058 ISSN: 0002-9165 * page 536, Abstract * * page 537, column 1; table 1 *	1, 2, 9, 18-20	A61K7/48 A61K35/78 A61K31/23 A61K31/07 A61K31/455 A61K31/355 A61K31/375 A61K33/04 A61P17/00 A23L1/30
X	US 4 970 235 A (TRAITLER HELMUT ET AL) 13 November 1990 (1990-11-13) * column 2, line 25 - column 3, line 3 * * examples 19, 20 * * claims 1, 2 *	20	
Y		1-6, 9, 18, 19	
Y	FR 2 720 647 A (ATHELIAPHARM SA) 8 December 1995 (1995-12-08) * page 18 - page 21; table *	1, 3-6, 18, 19	TECHNICAL FIELDS SEARCHED (Int.Cl.7) A61K A23L A61P
Y	DE 43 30 664 A (BEIERSDORF AG) 16 March 1995 (1995-03-16) * column 3, line 19 - column 6, line 7 * * claims 1-5 *	2-6, 9, 18, 19	
A	FR 2 773 484 A (MOREAU PIERRE) 16 July 1999 (1999-07-16) * page 1, line 17 - line 32 * * page 8, line 1 - page 9, line 30 * * page 10, line 19 - page 11, line 19 * * claims 1, 3, 4, 6, 8, 10, 12-15, 18 * --- -/-	1-20	
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 3 May 2001	Examiner Dekeirel, M
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons * : member of the same patent family, corresponding document</p>			

EPO FORM 1503/03:82 (P04C01)



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 01 40 0198

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
A	GB 2 254 556 A (FISONS PLC) 14 October 1992 (1992-10-14) * page 4, line 24 - page 5, line 1 * * page 5, line 19 - page 6, line 11 * * example 6 * * claims 1,21 *	1-20	
A	ZIBOH V A ET AL: "DOSE-RESPONSE EFFECTS OF DIETARY GAMMA-LINOLENIC ACID-ENRICHED OILSON HUMAN POLYMORPHONUCLEAR-NEUTROPHIL BIOSYNTHESIS OF LEUKOTRIENE B41-3" AMERICAN JOURNAL OF CLINICAL NUTRITION, BETHESDA, MD, US, vol. 55, no. 1, 1992, pages 39-45, XP000953018 ISSN: 0002-9165 * the whole document *	1-20	
			TECHNICAL FIELDS SEARCHED (Int.Cl.7)
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 3 May 2001	Examiner Dekeirel, M
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons S : member of the same patent family, corresponding document</p>			

EPO FORM 1533 (3.92) (P/M/C/01)

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 01 40 0198

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

03-05-2001

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 4970235 A	13-11-1990	AT 24266 T	15-01-1987
		AT 18572 T	15-03-1986
		AU 567091 B	12-11-1987
		AU 1308483 A	20-10-1983
		AU 555940 B	16-10-1986
		AU 1316983 A	20-10-1983
		CA 1195172 A	15-10-1985
		CA 1216592 A	13-01-1987
		CS 8302723 A	15-04-1992
		DE 3362492 D	17-04-1986
		DE 3368377 D	29-01-1987
		DK 165483 A	17-10-1983
		EP 0092076 A	26-10-1983
		EP 0092085 A	26-10-1983
		ES 521523 D	16-07-1985
		ES 8506188 A	01-11-1985
		ES 521524 D	01-12-1984
		ES 8500987 A	01-02-1985
		ES 540830 D	16-11-1985
		ES 8601842 A	01-03-1986
		FI 831172 A,B,	17-10-1983
		FI 831173 A,B,	17-10-1983
		GB 2118567 A,B	02-11-1983
		GR 78210 A	26-09-1984
		GR 78211 A	26-09-1984
		HK 83286 A	14-11-1986
		HU 185359 B	28-01-1985
		JP 1723581 C	24-12-1992
		JP 4004298 B	27-01-1992
		JP 58189110 A	04-11-1983
		JP 1055680 B	27-11-1989
		JP 1569005 C	10-07-1990
		JP 58192828 A	10-11-1983
		MY 14287 A	31-12-1987
		NO 831335 A	17-10-1983
		NO 831336 A,B,	17-10-1983
		NO 852357 A	17-10-1983
		NO 165525 B	19-11-1990
		NZ 203828 A	08-08-1986
		US 5011855 A	30-04-1991
		US 4938984 A	03-07-1990
		US 4526793 A	02-07-1985
		US 4703060 A	27-10-1987
		ZA 8302367 A	28-12-1983
		ZA 8302492 A	28-12-1983

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 01 40 0198

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

03-05-2001

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
FR 2720647	A	08-12-1995	NONE	
DE 4330664	A	16-03-1995	AU — 7657094 A	27-03-1995
			WO 9507091 A	16-03-1995
			EP 0720481 A	10-07-1996
			JP 9502196 T	04-03-1997
FR 2773484	A	16-07-1999	NONE	
GB 2254556	A	14-10-1992	NONE	

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82